TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05949866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement and Cognition Intervention Group
Description: Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Tracker Group (Control Group)
Description: Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
Study: NCT06363968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETeval
Description: as previous
Study: NCT05752227

Intervention type: PROCEDURE
Intervention: Transthoracic biopsy
Description: Us guided transthoracic biopsy

Intervention type: PROCEDURE
Intervention: Transthoracic biopsy
Description: Us guided transthoracic biopsy

Intervention type: RADIATION
Intervention: CT chest
Description: Computed tomography

Intervention type: RADIATION
Intervention: CT chest
Description: Computed tomography
Study: NCT05109598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
Study: NCT04881305

Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires and neuropsychological assessment
Description: Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.

Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires and neuropsychological assessment
Description: Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
Study: NCT05371951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HLS
Description: 84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
Study: NCT05626959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTI164
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study: NCT05300594

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant extracts, vitamins and mineral
Description: Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
Study: NCT05626959

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NTI164
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study: NCT05330429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study: NCT05478096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetStarted
Description: Guided internet-based intervention for procrastination.
Study: NCT05330429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously
Study: NCT06153563

Intervention type: OTHER
Intervention: Data collection on patient history and intraoperative results.
Description: Data collection on patient history and intraoperative results.
Study: NCT06407648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Assessments
Description: Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
Study: NCT05377476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery training
Description: Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation training
Description: Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation
Description: 40 minutes of standard rehabilitation.
Study: NCT05377476

Intervention type: OTHER
Group type: OTHER
Intervention: standard rehabilitation
Description: 40 minutes of standard rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation
Description: 40 minutes of standard rehabilitation.
Study: NCT06344052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-002
Description: SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-002
Description: SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vismodegib
Description: The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
Study: NCT06506175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 tablets
Description: HRS9531 tablets
Study: NCT05840185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses (DAL)
Description: A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
Study: NCT05549466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Description: Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib, Camrelizumab
Description: Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Description: Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
Description: Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
Study: NCT06401616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAC will be discontinued for the duration of the trial
Description: Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
Study: NCT05330429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously
Study: NCT06085404

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
Study: NCT06150352

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure or other management for OSA per clinical indications.
Description: PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
Study: NCT05643170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Study: NCT04706715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-REGN3767
Description: Anti-LAG-3 PET imaging tracer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-REGN3767
Description: Anti-LAG-3 PET imaging tracer
Study: NCT05570227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [U-13C]Glucose Infusion
Description: Peri-operative infusion of \[U-13C\]glucose
Study: NCT04706715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
Study: NCT05588076

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04953663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: it-hMSC
Description: Different doses of it-hMSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: it-hMSC
Description: Different doses of it-hMSC
Study: NCT05625230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation plus Dynamic Mental Imagery
Description: This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral activation
Description: The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity.
Study: NCT05710211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clonal architecture determination
Description: Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing
Study: NCT06353399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-marrow penetrations
Description: Intra-marrow penetrations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Intra-marrow penetrations
Description: No Intra-marrow penetrations
Study: NCT04837729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
Study: NCT05368103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daxdilimab
Description: Daxdilimab will be administered subcutaneously as two injections for each dose.
Study: NCT05089448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alisartan, Amlodipine besylate
Description: Drugs will be taken once daily at 6:00-10:00.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisartan, Amlodipine besylate
Description: Drugs will be taken once daily at 20:00-24:00.
Study: NCT06327633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training
Description: The subjects repeatedly sniffed pleasant scents of rose, lemon, clove, eucalyptus, coffee and cinnamon twice a day, 5-min per time, with focus, until the completion of the study.
Study: NCT04907149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 film-coated tablet
Description: Participants will receive a single oral dose of GLPG3970.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]GLPG3970 solution for infusion
Description: Participants will receive an i.v. microtracer microdose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14]GLPG3970 oral solution
Description: Participants will receive a single oral dose \[14C\]GLPG3970.
Study: NCT04953663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: it-hMSC
Description: Different doses of it-hMSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: it-hMSC
Description: Different doses of it-hMSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: it-hMSC
Description: Different doses of it-hMSC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: it-hMSC
Description: Different doses of it-hMSC
Study: NCT05474885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CD19 cCAR T cells
Description: BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study: NCT06300294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
Study: NCT06239519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Practice + JoyPop
Description: Participants will be asked to use the app at least twice daily but will otherwise not be provided with requirements related to feature or total usage.
Study: NCT05277701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
Study: NCT05384821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV, D1-D22-D43 and D64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-Retinoic acid
Description: Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
Study: NCT05123079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Tablets
Study: NCT04919694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combination of orbital compression surgery and strabismus surgery
Description: combination of orbital compression surgery and strabismus surgery at the same time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital compression
Description: orbital compression
Study: NCT04443517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alpha Optimization
Description: Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Optimization
Description: Intraoperative oscillatory EEG alpha optimization involves real-time acquisition of oscillatory alpha power from the frontal EEG with individualized titration of desflurane and opioid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergence from anesthesia with propofol
Description: Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emergence from anesthesia with propofol
Description: Infusion of 400 mg/h of propofol during the final 10-20 minutes of surgery. Total doses of propofol administered are likely to be in the range of 1-3 mg/kg.
Study: NCT05237999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KopOpOuders-PTSD
Description: See arm description
Study: NCT06261437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCAR
Description: The CCAR will be consumed as the sole source of nutrition during a 7-day military training exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FSR
Description: The FSR will be consumed as the sole source of nutrition during a 7-day military training exercise.
Study: NCT06327282

Intervention type: BEHAVIORAL
Intervention: education on pain and related knowledge
Description: Before surgery, pain related knowledge was educated.